ELICIT-PLANT
11.3.2024 10:01:30 CET | Business Wire | Press release
Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO). An author of more than 20 patent family applications in the space of biomolecular and biological innovations for plant stress, her appointment reflects Elicit Plant's commitment to accelerating the transition towards sustainable and environmentally friendly agriculture. Slavica Djonovic's mission is to propel the company to a new level of innovation by developing cutting-edge solutions to help farmers worldwide combat water stress and scarcity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240308898928/en/
Slavica Djonovic, Chief Scientific Officer (Photo: Elicit Plant)
A remarkable scientific and leadership career
With over two decades of ag-tech experience, Slavica Djonovic is a respected scientific leader in the field of research and development of biological products for agriculture, especially in broad acre crops.
Slavica holds a Master of Science from Colorado State University, a Ph.D. from Texas A&M University, and she has completed her postdoctoral training at Massachusetts General Hospital and Harvard Medical School.
Her entrepreneurial spirit led her to be one of the founding scientists of Indigo Ag, a Boston-based agricultural biotechnology company. There, she played a key role as Director of Product Science, making significant contributions to product discovery, development, intellectual property, regulatory, and the launch of the company's first five microbial products. At Joyn Bio, a synthetic biology Agtech company in Boston (US), she served as Senior Director by establishing the disease control program and initiating the regulatory science approach, thus solidifying her reputation as a leader in agrotechnological innovation.
An expertise aligned with Elicit Plant's high ambitions
With a track record of over 20 patent applications in innovations related to plant stress, the vast majority of which have been internationally granted, Slavica Djonovic brings to Elicit Plant cutting-edge technical expertise and a unique strategic vision, precisely at a time when Elicit Plant is preparing to enter a new critical period of growth and innovation.
"Faced with the challenges posed by climate change, it is imperative that our agricultural sector quickly embraces innovative solutions to ensure a healthy and sustainable future for all. I am honored to join Elicit Plant, a booming pioneer in the agricultural sector, empowering farmers to effectively tackle climate upheavals. Elicit Plant's proprietary technology, EliTerra®, the consistent performance of its products internationally, and its team driven by a clear mission, are impressive," states Slavica Djonovic, CSO of Elicit Plant.
"In her new role as Chief Scientific Officer, Slavica will be tasked with amplifying Elicit Plant's scientific influence and accelerating the development of our EliTerra® Technological platform. Slavica brings with her a wealth of knowledge and unparalleled experience that will be essential levers for our evolution. We are convinced that under her scientific leadership, Elicit Plant will reach a new milestone in developing innovative solutions for agriculture," concludes Jean-François Déchant, CEO of Elicit Plant.
For more information: https://www.elicit-plant.com/press-resources/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240308898928/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 16:30:00 CEST | Press release
Companies team to deliver a unified, enterprise-scale agentic stack to help organizations with managing data sovereignty and optimizing AI costs Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexi
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 16:30:00 CEST | Press release
Partnership enables customers to accelerate AI agents from pilot to production with accuracy, performance, and control by combining Boomi's connectivity, agent runtime, and governance with Couchbase's operational data platform Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recolle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom